Assignee
LANTERN PHARMA INC
US·3 granted patents·19 pending applications·2 citations·filing 2015–2025
Top patents by PatentIndex Score
22 records- 0183US11844772B2Method for treating rhabdoid tumorsLANTERN PHARMA INC·Filed 2021·Granted Dec 19, 2023·1 cites·20 claims
- 0273US11471431B2Increasing cancer patient survival time by administration of dithio-containing compoundsLANTERN PHARMA INC·Filed 2015·Granted Oct 18, 2022·1 cites·8 claims
- 0373US2026011400A1Machine learning system and method for predicting blood brain barrier permeabilityLANTERN PHARMA INC·Filed 2025·Application pending·0 cites
- 0470US2023399285A1Illudin analogs, uses thereof, and methods for synthesizing the sameLANTERN PHARMA INC·Filed 2023·Application pending·0 cites
- 0569US2023210794A1Increasing Cancer Patient Survival Time by Administration of Dithio-Containing CompoundsLANTERN PHARMA INC·Filed 2022·Application pending·0 cites
- 0667US11739043B2Illudin analogs, uses thereof, and methods for synthesizing the sameLANTERN PHARMA INC·Filed 2021·Granted Aug 29, 2023·0 cites·5 claims
- 0761US2024428886A1Computerized systems and methods for ensemble model-based drug discoveryLANTERN PHARMA INC·Filed 2024·Application pending·0 cites
- 0860US2023304104A1Cancer drug sensitivity determining markersLANTERN PHARMA INC·Filed 2023·Application pending·0 cites
- 0958US2024398732A1Treating Cancers with Combinations of Spironolactone and AcylfulvenesLANTERN PHARMA INC·Filed 2024·Application pending·0 cites
- 1058US2025099406A1Treating cancers with combinations of acylfulvenes with ibrutinib and/or bortezomibLANTERN PHARMA INC·Filed 2024·Application pending·0 cites
- 1158US2024299322A1Treating cancers with combinations of parp inhibitor and acylfulvenesLANTERN PHARMA INC·Filed 2024·Application pending·0 cites
- 1257US2024082181A1Method for Treating Blood CancersLANTERN PHARMA INC·Filed 2023·Application pending·0 cites
- 1357US2024325328A1Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulveneLANTERN PHARMA INC·Filed 2023·Application pending·0 cites
- 1456US2023220481A1Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane SulfonateLANTERN PHARMA INC·Filed 2022·Application pending·0 cites
- 1555US2026083691A1Treating cancers with combinations of anti-cd20 antibody and acylfulvenesLANTERN PHARMA INC·Filed 2025·Application pending·0 cites
- 1654US2024299316A1Method for treating cancer with acylfulvene and radiationLANTERN PHARMA INC·Filed 2024·Application pending·0 cites
- 1751US2022168258A1Method for treating female non-smokers with non-small cell lung cancerLANTERN PHARMA INC·Filed 2021·Application pending·0 cites
- 1851US2026007617A1Method for treating renal cell carcinoma or cancerLANTERN PHARMA INC·Filed 2025·Application pending·0 cites
- 1950US2023172882A1Method For Treating Pancreatic CancerLANTERN PHARMA INC·Filed 2021·Application pending·0 cites
- 2050US2021230662A1Methods for the Treatment of Solid Tumor Cancers Using Illudins and BiomarkersLANTERN PHARMA INC·Filed 2021·Application pending·0 cites
- 2149US2023181499A1Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS CancerLANTERN PHARMA INC·Filed 2021·Application pending·0 cites
- 2240US2025161247A1Method for treating breast cancers and parp resistant breast cancersLANTERN PHARMA INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LANTERN PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →